Effects of anastrozole on lipid metabolism compared with tamoxifen in rats

Breast Cancer Research and Treatment

Volumn 76, Issue 2, 2002, Pages 131-136

  Hozumi, Yasuo ^a   Hakamata, Yoji ^a   Sasanuma, Hideki ^a   Ogura, Shigeto ^a   Nagai, Hideo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Anastrozole; Lipid metabolism; Lipoprotein lipase activity; Tamoxifen

Indexed keywords

ANASTROZOLE; CHOLESTEROL; HEPARIN; LIPID; LIPOPROTEIN LIPASE; TAMOXIFEN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; LIPID BLOOD LEVEL; LIPID METABOLISM; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; CHOLESTEROL; DRUG COMBINATIONS; ENZYME INHIBITORS; FEMALE; LIPOPROTEIN LIPASE; NITRILES; RATS; TAMOXIFEN; TRIAZOLES; TRIGLYCERIDES;

EID: 0036829442     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020571617274     Document Type: Article

References (35)

1. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocrine Rev 11: 221-265, 1990
2. Buzdar AU, Jones SE, Vogal CL, Wolter J, Plourde P, Webster A: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79: 730-739, 1997
3. Lonning PE, Lien E: Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Haematol 21: 158-193, 1995
4. Murphy MJ: Molecular action and clinical relevance of aromatase inhibitors. Oncology 3: 129-130, 1998
5. Murray R: Role of anti-aromatase agents in postmenopausal advanced breast cancer. Cancer Chemother Pharmacol 48: 259-265, 2001
6. Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A: Arimidex: A new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53: 175-179, 1995
7. Geisler J, King N, Dowsett M, Ottestad I, Lundgren S, Walton P, Kormeset PO, Lonning PE: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74: 1286-1291, 1996
8. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangallk A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North Americans multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767, 2000
9. Bonneterre J, Robertson JF, Thurlimann B, Krzakowski M, Maurlac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748-3757, 2000
10. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M: Arimidex Writing Committee; Investigators Committee Members: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92: 2247-2258, 2001
11. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19: 881-894, 2001
12. Ragaz J: Adjuvant trials of aromatase inhibitors: Determining the future landscape of adjuvant endocrine therapy. J Steroid Biochem Mol Biol 79: 133-141, 2001
13. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20: 751-757, 2002
14. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V. Robidoux A, Dimitrov N, Atkins J, Daly M. Wieand S, Tan-Chiu E, Ford L, Wolmark N: National Surgical Adjuvant Breast and Bowel Project Investigators: Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371-1388, 1998
15. Grainger DJ, Metcalfe JC: Tamoxifen: Teaching an old drug new tricks? Nature Med 2: 381-385, 1996
16. MacGregor JI, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Phannacol Rev 50: 151-196, 1998
17. Kinnunen PKJ, Virtanen JA, Vaino P: Lipoprotein lipase and hepatic endothelial lipase: Their roles in plasma lipoprotein metabolism. Atheroscler Rev 11: 65-105, 1983
18. Auwerx J, Leroy P, Schoonjans K: Lipoprotein lipase: Recent contributions from molecular biology. Crit Rev Clin Lab Sci 29: 243-268, 1992
19. Hozumi Y, Kawano M, Miyata M: Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocrine J 44: 745-749, 1997
20. Hozumi Y, Kawano M. Saito T, Miyata M: Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 83: 1633-1635, 1998
21. Brun LD, Gagne C, Rousseau C, Moorjanis S, Lupien PJ: Severe lipemia induced by tamoxifen. Cancer 57: 2123-2126, 1986
22. Hozumi Y, Kawano M, Hakamata Y, Miyata M, Jordan VC: Tamoxifen inhibits lipoprotein activity: In vivo and in vitro studies. Horm Res 53: 36-39, 2000
23. Belfrage P, Vaughan M: Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures of glycerides. J Lipid Res 10: 341-344, 1969
24. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Int Medicine 115: 860-864, 1991
25. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen trial. BMJ 303: 435-437, 1991
26. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 85: 1398-1406, 1993
27. Love RR, Wiebe DA, Feyzi JM, Newcomb PA: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86: 1534-1539, 1994
28. Grey AB, Stapleton JP, Evans MC, Reid IR: The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80: 3191-3195, 1995
29. Mikhailidis DP, Ganotakis ES, Georgoulias VA, Vallance VT, Winder AF: Tamoxifen-induced hypertriglyceridemia: Seven cases reports and suggestions for remedial action. Oncol Rep 4: 625-628, 1997
30. Colls BM, George PM: Severe hypertriglyceridaemia and hypercholesteroleamia associated with tamoxifen use. Clin Oncol (R Coll Radiol) 10: 270-271, 1998
31. Castelli WP: The triglyceride issue: A view from Framingham. Am Heart J 112: 432-437, 1986
32. Gaziano JM, Hennekens CH, Odonnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96: 2520-2525, 1997
33. Elisaf MS, Bairaktari Eth, Nicolaides C, Kakaidi B, Tzallas CS, Kastraki A, Pavlidis NA: Effects of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37: 1510-1513, 2001
34. Price TM, O'Brien SN, Welter BH, George R, Anandjiwala J, Kilgore M: Estrogen regulation of adipose tissue lipoprotein lipase - Possible mechanism of body fat distribution. Am J Obstet Gynecol 178: 101-107, 1998
35. Ploude PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30: 103-111, 1994